Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HDAC-42

Known as: AR-42, HDAC Inhibitor AR-42, OSU-HDAC42 
An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, AR… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Cancer cachexia is a debilitating condition that impacts patient morbidity, mortality, and quality of life and for… Expand
Is this relevant?
2015
2015
Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy… Expand
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
A neurogenesis defect in a mouse model of Kabuki syndrome can be ameliorated postnatally using histone deacetylase inhibitors… Expand
Is this relevant?
2013
2013
Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Histone hypoacetylation occurs in many cancers and inhibition of histone deacetylation is a promising approach to modulate these… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Drug… Expand
Is this relevant?
2010
2010
Background While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
The cytomegalovirus (CMV) promoter is considered to be one of the strongest promoters for driving the in vivo expression of genes… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
This study reports a histone deacetylation-independent mechanism whereby histone deacetylase (HDAC) inhibitors sensitize prostate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?